Stocks
Pfizer Inc.PFE
NYSEHealthcarePharmaceuticals$26.60-0.97%
One of the largest global biopharmaceutical companies, it develops and manufactures prescription medicines and vaccines across oncology, immunology, cardiology, and infectious diseases. Revenue has been heavily influenced in recent years by COVID-19 vaccine and antiviral sales, with investors closely monitoring product pipeline development, patent expirations, and acquisition strategy to offset declining pandemic-related revenue. The stock is widely held for its dividend profile and exposure to large-cap pharmaceutical cash flows.
Market Cap: $151.3B52W Range: $20.92 – $27.94
Congressional Interest in Pfizer Inc. (PFE)
13 members of Congress have disclosed 50 trades in Pfizer Inc. (PFE), a Healthcare company. The buy/sell breakdown shows 20 purchases versus 30 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
50
Unique Politicians
13
Buys
20
Sells
30
Who in Congress Is Trading PFE?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2009-10-07 | MICHAEL T. MCCAUL | sell | $1K – $15K |
| 2009-09-11 | Kurt Schrader | buy | $3,734.89 |